Đang chuẩn bị liên kết để tải về tài liệu:
Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: Design and rationale of randomized controlled trial

Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome since obesity and insulin resistance are the main pathogenic contributors for both conditions. NAFLD carries increased risk of atherosclerosis and cardiovascular diseases. | Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: Design and rationale of randomized controlled trial